A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of KRN23 after its 48-week
once every 4 weeks repeated subcutaneous administration to Japanese and Korean patients with
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome by a multicenter, open-label,
intraindividual dose adjustment study